- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07942792
Evaluation of Unexplained Severe Syncope in a Modern Syncope Unit (Diamond)
Evidence-based Evaluation of Unexplained Severe Syncope in a Modern Syncope Unit: an Observational Study
The aim of the present study is to evaluate clinical practice in the diagnosis of severe unexplained syncope among European Syncope Units adhering to the standards set forth by the ESC guidelines.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The Diamond study is an investigator-initiated, prospective, international, multicenter study, coordinated by the non-profit organization Gruppo Italiano Studio Sincope (GIMSI), conducted within European Syncope Units that fulfill the personnel and equipment criteria recommended by the European Heart Rhythm Association (EHRA) and the (GIMSI) (https://www.gimsi.it/modello-organizzativo/).
Eligibility of each center is certified by the head of the syncope unit, who completes a questionnaire confirming compliance with the required standards. Web-based Clinical Report Form (CRF). To allow uniform clinical data collection from participating centres, a web-based CRF, was designed Study workflow. Following documented patient consent, clinical personnel at the site -trained in the use of the web-app- will access the digital tool to enter the patient's I/E criteria assessment, personal information and medical history. From that point forward, data will be entered into the web-app on an ongoing basis, in accordance with the site's routine clinical practice, until the patient reaches a defined exit point (such as diagnosis of cardiac syncope, diagnosis of autonomic syncope, no syncope, no diagnosis), or drop-out (e.g., patient death, patient unable to comply with diagnostic pathway, etc.).
Type d'étude
Inscription (Estimé)
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Consecutive patients referred to the Syncope Unit for severe unexplained syncope
La description
Inclusion Criteria: Outpatients aged ≥16 years referred to the Syncope Unit due to severe, unexplained syncope and/or unexplained fall requiring comprehensive evaluation to identify the most appropriate mechanism-specific therapy.
Exclusion Criteria: Non-severe syncope Definitions.
-
Unexplained syncope is defined as unexplained etiology or unexplained
-
Severe syncope is defined by the presence of one or more among the following:
-
Suspected life-threatening arrhythmias
-
Substantial impact on patient's quality of life (QoL)
- Frequent episodes
- Restriction of educational or occupational activities (including, but not limited to, unemployment)
- Restriction of social or daily-life activities, e.g. when syncope occurs while driving
-
High risk of clinically significant outcomes
- Syncope associated with major injuries/trauma, i.e. head injury or fractures
- Unpredictable syncope, i.e. without prodrome or identifiable triggers
-
Presence of serious comorbidities, such as concomitant heart disease, neurologic disease, diabetes or renal failure
-
Suspected Autonomic syncope overlapping with suspected psychogenic pseudosyncope
-
-
Non-severe syncope is defined by the presence of one or more among the following:
- Sporadic (isolated) episodes without major impact on patient's QoL
- Predictable syncope, i.e. syncope preceded by prodrome and/or occurring in association with identifiable triggers, with low risk of injuries
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Unexplained syncope
Syncope Unit |
At the initial evaluation, it is essential to exclude non-syncopal causes of transient loss of consciousness (TLOC) - such as epilepsy, psychogenic pseudosyncope, and other conditions of apparent loss of consciousness that may be incorrectly diagnosed as syncope. Once non-syncopal causes have been excluded and the loss of consciousness is determined to be syncopal in nature, the primary objective of the diagnostic work-up is to identify cases of cardiac syncope. Cardiac syncope is characterized by loss of consciousness due to a primary cardiac disorder, such as arrhythmias or structural heart disease, and requires prompt recognition and appropriate treatment due to its association with higher morbidity and mortality. When both cardiac syncope and non-syncopal causes of TLOC are reasonably ruled out, the diagnosis of autonomic syncope becomes likely. Autonomic syncope encompasses both reflex (neurally mediated) syncope and orthostatic hypotension and represents the most frequent cause |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Rate of final diagnoses 2) Type of final diagnoses 3) Number of tests utilized to reach them.
Délai: through study completion, an average of 1 year
|
through study completion, an average of 1 year
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
Number of participants with adherence of the clinical practices to a theoretical diagnostic pathway
Délai: through study completion, an average of 1 year
|
through study completion, an average of 1 year
|
|
Assessment of number and costs of resource utilization associated to the clinical practices
Délai: through study completion, an average of 1 year
|
through study completion, an average of 1 year
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 09X605
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .